Show simple item record

dc.creatorAntonijević, Nebojša
dc.creatorŽivković, Ivana D.
dc.creatorJovanović, Ljubica M.
dc.creatorMatić, Dragan
dc.creatorKocica, Mladen J.
dc.creatorMrdović, Igor
dc.creatorKanjuh, Vladimir
dc.creatorĆulafić, Milica
dc.date.accessioned2019-09-02T11:57:04Z
dc.date.available2019-09-02T11:57:04Z
dc.date.issued2017
dc.identifier.issn1389-2002
dc.identifier.urihttp://farfar.pharmacy.bg.ac.rs/handle/123456789/2783
dc.description.abstractBackground: The superiority of dabigatran has been well proven in the standard dosing regimen in prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and extended venous thromboembolism (VTE) treatment. Dabigatran, an anticoagulant with a good safety profile, reduces intracranial bleeding in patients with atrial fibrillation and decreases major and clinically relevant non-major bleeding in acute VTE treatment. However, several important clinical issues are not fully covered by currently available directions with regard to dabigatran administration. The prominent one is reflected in the fact that dynamic impairment in renal function due to dehydratation may lead to haemorragic complications on the one hand, while on the other hand glomerular hyperfiltration may be a possible cause of dabigatran subdosing, hence reducing the drug's efficacy. Furthermore, limitations of the Cockcroft-Gault formula, considered a standard equation for assessing the renal function, may imply that other calculations are likely to obtain more accurate estimates of the kidney function in specific patient populations. Method and Conclusions: Although not routinely recommended, a possibility of monitoring dabigatran in special clinical settings adds to optimization of its dosage regimens, timely perioperative care and administration of urgently demanded thrombolytic therapy, therefore significantly improving this drug's safety profile. Despite the fact that dabigatran has fewer reported interactions with drugs, food constituents, and dietary supplements, certain interactions still remain, requiring considerable caution, notably in elderly, high bleeding risk patients, patients with decreased renal function and those on complex drug regimens. Additionally, upon approval of idarucizumab, an antidote to dabigatran solution, hitherto being a major safety concern, has been finally reached, which plays a vital role in life-threatening bleeding and emergency interventions and surgery.en
dc.publisherBentham Science Publ Ltd, Sharjah
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/173008/RS//
dc.rightsrestrictedAccess
dc.sourceCurrent Drug Metabolism
dc.titleDabigatran - Metabolism, Pharmacologic Properties and Drug Interactionsen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractЋулафић, Милица; Коцица, Младен Ј.; Aнтонијевић, Небојша; Кањух, Владимир; Живковић, Ивана Д.; Мрдовић, Игор; Јовановић, Љубица М.; Матић, Драган;
dc.citation.volume18
dc.citation.issue7
dc.citation.spage622
dc.citation.epage635
dc.citation.other18(7): 622-635
dc.citation.rankM22
dc.identifier.wos000409908500004
dc.identifier.doi10.2174/1389200218666170427113504
dc.identifier.pmid28460624
dc.identifier.scopus2-s2.0-85036571816
dc.identifier.rcubconv_3938
dc.type.versionpublishedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record